Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 75 entries
Sorted by: Best Match Show Resources per page
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.

Cells

Abbas R, Larisch S.
PMID: 34943974
Cells. 2021 Dec 08;10(12). doi: 10.3390/cells10123465.

Apoptosis is a cell suicide process that is essential for development, tissue homeostasis and human health. Impaired apoptosis is associated with a variety of human diseases, including neurodegenerative disorders, autoimmunity and cancer. As the levels of pro- and anti-apoptotic...

Cite
Abbas R, Larisch S. Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System. Cells. 2021;10(12)doi: 10.3390/cells10123465.
Abbas, R., & Larisch, S. (2021). Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System. Cells, 10(12), . https://doi.org/10.3390/cells10123465
Abbas, Ruqaia, and Larisch, Sarit. "Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System." Cells vol. 10,12 (2021). doi: https://doi.org/10.3390/cells10123465
Abbas R, Larisch S. Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System. Cells. 2021 Dec 08;10(12). doi: 10.3390/cells10123465. PMID: 34943974.
Copy Download .nbib Format: NLM
Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells.

Oncology reports

Horibe S, Ishikawa K, Nakada K, Wake M, Takeda N, Tanaka T, Kawauchi S, Sasaki N, Rikitake Y.
PMID: 34935060
Oncol Rep. 2022 Feb;47(2). doi: 10.3892/or.2021.8243. Epub 2021 Dec 22.

The efficacy of cisplatin (CDDP) has been demonstrated in the treatment of various cancers as monotherapy and combination therapy with immunotherapy. However, acquired CDDP resistance is a major obstacle to successful treatment. In the present study, the mechanisms underlying...

Cite
Horibe S, Ishikawa K, Nakada K, et al. Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells. Oncol Rep. 2021;47(2)doi: 10.3892/or.2021.8243.
Horibe, S., Ishikawa, K., Nakada, K., Wake, M., Takeda, N., Tanaka, T., Kawauchi, S., Sasaki, N., & Rikitake, Y. (2022). Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells. Oncology reports, 47(2), . https://doi.org/10.3892/or.2021.8243
Horibe, Sayo, et al. "Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells." Oncology reports vol. 47,2 (2022). doi: https://doi.org/10.3892/or.2021.8243
Horibe S, Ishikawa K, Nakada K, Wake M, Takeda N, Tanaka T, Kawauchi S, Sasaki N, Rikitake Y. Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells. Oncol Rep. 2022 Feb;47(2). doi: 10.3892/or.2021.8243. Epub 2021 Dec 22. PMID: 34935060.
Copy Download .nbib Format: NLM
Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs.

Frontiers in oncology

Guo W, Ma X, Fu Y, Liu C, Liu Q, Hu F, Miao H, Zhang T, Liu Y, Han MH, You F, Yang Y, Zheng W.
PMID: 33869021
Front Oncol. 2021 Mar 31;11:635233. doi: 10.3389/fonc.2021.635233. eCollection 2021.

Survivin as a member of the inhibitor of apoptosis proteins (IAPs) family is undetectable in normal cells, but highly expressed in cancer cells and cancer stem cells (CSCs) which makes it an attractive target in cancer therapy. Survivin dominant...

Cite
Guo W, Ma X, Fu Y, et al. Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs. Front Oncol. 2021;11:635233doi: 10.3389/fonc.2021.635233.
Guo, W., Ma, X., Fu, Y., Liu, C., Liu, Q., Hu, F., Miao, H., Zhang, T., Liu, Y., Han, M. H., You, F., Yang, Y., & Zheng, W. (2021). Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs. Frontiers in oncology, 11635233. https://doi.org/10.3389/fonc.2021.635233
Guo, Wei, et al. "Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs." Frontiers in oncology vol. 11 (2021): 635233. doi: https://doi.org/10.3389/fonc.2021.635233
Guo W, Ma X, Fu Y, Liu C, Liu Q, Hu F, Miao H, Zhang T, Liu Y, Han MH, You F, Yang Y, Zheng W. Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs. Front Oncol. 2021 Mar 31;11:635233. doi: 10.3389/fonc.2021.635233. eCollection 2021. PMID: 33869021; PMCID: PMC8045750.
Copy Download .nbib Format: NLM
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Clinical cancer research : an official journal of the American Association for Cancer Research

Le Tourneau C, Tao Y, Gomez-Roca C, Cristina V, Borcoman E, Deutsch E, Bahleda R, Calugaru V, Modesto A, Rouits E, Gollmer K, Vuagniaux G, Crompton P, Zanna C, Szyldergemajn S, Delord JP, Bourhis J.
PMID: 32994295
Clin Cancer Res. 2020 Dec 15;26(24):6429-6436. doi: 10.1158/1078-0432.CCR-20-0425. Epub 2020 Sep 29.

PURPOSE: Debio 1143 is an oral antagonist of inhibitor of apoptosis proteins, which enhances tumor response with concomitant chemoradiotherapy. Addition of Debio 1143 to cisplatin-based chemoradiotherapy in locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN) was...

Cite
Le Tourneau C, Tao Y, Gomez-Roca C, et al. Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2020;26(24):6429-6436doi: 10.1158/1078-0432.CCR-20-0425.
Le Tourneau, C., Tao, Y., Gomez-Roca, C., Cristina, V., Borcoman, E., Deutsch, E., Bahleda, R., Calugaru, V., Modesto, A., Rouits, E., Gollmer, K., Vuagniaux, G., Crompton, P., Zanna, C., Szyldergemajn, S., Delord, J. P., & Bourhis, J. (2020). Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(24), 6429-6436. https://doi.org/10.1158/1078-0432.CCR-20-0425
Le Tourneau, Christophe, et al. "Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,24 (2020): 6429-6436. doi: https://doi.org/10.1158/1078-0432.CCR-20-0425
Le Tourneau C, Tao Y, Gomez-Roca C, Cristina V, Borcoman E, Deutsch E, Bahleda R, Calugaru V, Modesto A, Rouits E, Gollmer K, Vuagniaux G, Crompton P, Zanna C, Szyldergemajn S, Delord JP, Bourhis J. Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2020 Dec 15;26(24):6429-6436. doi: 10.1158/1078-0432.CCR-20-0425. Epub 2020 Sep 29. PMID: 32994295.
Copy Download .nbib Format: NLM
Molecular and Functional Characterization of Inhibitor of Apoptosis Proteins (IAP, BIRP) in .

Frontiers in microbiology

Zhan J, Song H, Wang N, Guo C, Shen N, Hua R, Shi Y, Angel C, Gu X, Xie Y, Lai W, Peng X, Yang G.
PMID: 32390980
Front Microbiol. 2020 Apr 22;11:729. doi: 10.3389/fmicb.2020.00729. eCollection 2020.

The larval stage of

Cite
Zhan J, Song H, Wang N, et al. Molecular and Functional Characterization of Inhibitor of Apoptosis Proteins (IAP, BIRP) in . Front Microbiol. 2020;11:729doi: 10.3389/fmicb.2020.00729.
Zhan, J., Song, H., Wang, N., Guo, C., Shen, N., Hua, R., Shi, Y., Angel, C., Gu, X., Xie, Y., Lai, W., Peng, X., & Yang, G. (2020). Molecular and Functional Characterization of Inhibitor of Apoptosis Proteins (IAP, BIRP) in . Frontiers in microbiology, 11729. https://doi.org/10.3389/fmicb.2020.00729
Zhan, Jiafei, et al. "Molecular and Functional Characterization of Inhibitor of Apoptosis Proteins (IAP, BIRP) in ." Frontiers in microbiology vol. 11 (2020): 729. doi: https://doi.org/10.3389/fmicb.2020.00729
Zhan J, Song H, Wang N, Guo C, Shen N, Hua R, Shi Y, Angel C, Gu X, Xie Y, Lai W, Peng X, Yang G. Molecular and Functional Characterization of Inhibitor of Apoptosis Proteins (IAP, BIRP) in . Front Microbiol. 2020 Apr 22;11:729. doi: 10.3389/fmicb.2020.00729. eCollection 2020. PMID: 32390980; PMCID: PMC7188921.
Copy Download .nbib Format: NLM
Downregulation of inhibitor of apoptosis protein induces apoptosis and suppresses stemness maintenance in testicular teratoma.

Experimental and therapeutic medicine

Li G, Liao M, Li S, You J, Wang J, Lei W, Yang C, Xu H, Xiao H, Chen H.
PMID: 34675993
Exp Ther Med. 2021 Dec;22(6):1399. doi: 10.3892/etm.2021.10835. Epub 2021 Oct 01.

Inhibitors of apoptosis (IAPs) are a family of cell death inhibitors found in viruses and metazoans that physically interact with a variety of pro-apoptotic proteins and inhibit apoptosis induced by diverse stimuli. Melanoma IAP (ML-IAP) is a potent anti-apoptotic...

Cite
Li G, Liao M, Li S, et al. Downregulation of inhibitor of apoptosis protein induces apoptosis and suppresses stemness maintenance in testicular teratoma. Exp Ther Med. 2021;22(6):1399doi: 10.3892/etm.2021.10835.
Li, G., Liao, M., Li, S., You, J., Wang, J., Lei, W., Yang, C., Xu, H., Xiao, H., & Chen, H. (2021). Downregulation of inhibitor of apoptosis protein induces apoptosis and suppresses stemness maintenance in testicular teratoma. Experimental and therapeutic medicine, 22(6), 1399. https://doi.org/10.3892/etm.2021.10835
Li, Gang, et al. "Downregulation of inhibitor of apoptosis protein induces apoptosis and suppresses stemness maintenance in testicular teratoma." Experimental and therapeutic medicine vol. 22,6 (2021): 1399. doi: https://doi.org/10.3892/etm.2021.10835
Li G, Liao M, Li S, You J, Wang J, Lei W, Yang C, Xu H, Xiao H, Chen H. Downregulation of inhibitor of apoptosis protein induces apoptosis and suppresses stemness maintenance in testicular teratoma. Exp Ther Med. 2021 Dec;22(6):1399. doi: 10.3892/etm.2021.10835. Epub 2021 Oct 01. PMID: 34675993; PMCID: PMC8524704.
Copy Download .nbib Format: NLM
Expression and clinical significance of Apollon in renal carcinoma.

Oncology letters

Guo H, Zhong W, Wang X, Pan B, Li F, Lu K, Su Z, Zhang S.
PMID: 28105219
Oncol Lett. 2016 Dec;12(6):5129-5135. doi: 10.3892/ol.2016.5349. Epub 2016 Nov 03.

Apollon, namely baculoviral inhibitor of apoptosis proteins (IAP) repeat containing 6, is an unusually large member of the IAP family, and may be important in oncogenesis. The aim of the present study was to assess the association between renal...

Cite
Guo H, Zhong W, Wang X, et al. Expression and clinical significance of Apollon in renal carcinoma. Oncol Lett. 2016;12(6):5129-5135doi: 10.3892/ol.2016.5349.
Guo, H., Zhong, W., Wang, X., Pan, B., Li, F., Lu, K., Su, Z., & Zhang, S. (2016). Expression and clinical significance of Apollon in renal carcinoma. Oncology letters, 12(6), 5129-5135. https://doi.org/10.3892/ol.2016.5349
Guo, Hongbo, et al. "Expression and clinical significance of Apollon in renal carcinoma." Oncology letters vol. 12,6 (2016): 5129-5135. doi: https://doi.org/10.3892/ol.2016.5349
Guo H, Zhong W, Wang X, Pan B, Li F, Lu K, Su Z, Zhang S. Expression and clinical significance of Apollon in renal carcinoma. Oncol Lett. 2016 Dec;12(6):5129-5135. doi: 10.3892/ol.2016.5349. Epub 2016 Nov 03. PMID: 28105219; PMCID: PMC5228483.
Copy Download .nbib Format: NLM
Induction of Apoptosis and Cell Cycle Arrest by Flavokawain C on HT-29 Human Colon Adenocarcinoma via Enhancement of Reactive Oxygen Species Generation, Upregulation of p21, p27, and GADD153, and Inactivation of Inhibitor of Apoptosis Proteins.

Pharmacognosy magazine

Phang CW, Karsani SA, Abd Malek SN.
PMID: 28808400
Pharmacogn Mag. 2017 Jul;13:S321-S328. doi: 10.4103/0973-1296.210180. Epub 2017 Jul 11.

Chalcones have been shown to exhibit anti-cancer properties by targeting multiple molecular pathways. It was, therefore, of interest to investigate flavokawain C (FKC), a naturally occurring chalcone, which can be isolated from Kava (SUMMARY: Flavokawain C inhibited the growth...

Cite
Phang CW, Karsani SA, Abd Malek SN. Induction of Apoptosis and Cell Cycle Arrest by Flavokawain C on HT-29 Human Colon Adenocarcinoma via Enhancement of Reactive Oxygen Species Generation, Upregulation of p21, p27, and GADD153, and Inactivation of Inhibitor of Apoptosis Proteins. Pharmacogn Mag. 2017;13:S321-S328doi: 10.4103/0973-1296.210180.
Phang, C. W., Karsani, S. A., & Abd Malek, S. N. (2017). Induction of Apoptosis and Cell Cycle Arrest by Flavokawain C on HT-29 Human Colon Adenocarcinoma via Enhancement of Reactive Oxygen Species Generation, Upregulation of p21, p27, and GADD153, and Inactivation of Inhibitor of Apoptosis Proteins. Pharmacognosy magazine, 13S321-S328. https://doi.org/10.4103/0973-1296.210180
Phang, Chung-Weng, et al. "Induction of Apoptosis and Cell Cycle Arrest by Flavokawain C on HT-29 Human Colon Adenocarcinoma via Enhancement of Reactive Oxygen Species Generation, Upregulation of p21, p27, and GADD153, and Inactivation of Inhibitor of Apoptosis Proteins." Pharmacognosy magazine vol. 13 (2017): S321-S328. doi: https://doi.org/10.4103/0973-1296.210180
Phang CW, Karsani SA, Abd Malek SN. Induction of Apoptosis and Cell Cycle Arrest by Flavokawain C on HT-29 Human Colon Adenocarcinoma via Enhancement of Reactive Oxygen Species Generation, Upregulation of p21, p27, and GADD153, and Inactivation of Inhibitor of Apoptosis Proteins. Pharmacogn Mag. 2017 Jul;13:S321-S328. doi: 10.4103/0973-1296.210180. Epub 2017 Jul 11. PMID: 28808400; PMCID: PMC5538174.
Copy Download .nbib Format: NLM
Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells.

Frontiers in oncology

Lehman CE, Mendez RE, Dougherty MI, Allak A, Adejumo OL, Taniguchi LE, Khalil A, Gioeli DG, Jameson MJ.
PMID: 30729097
Front Oncol. 2019 Jan 23;9:13. doi: 10.3389/fonc.2019.00013. eCollection 2019.

Epidermal growth factor receptor (EGFR) inhibitors have limited efficacy in head and neck squamous cell carcinoma (HNSCC) due to various resistance mechanisms, such as activation of the insulin-like growth factor-1 receptor (IGF1R), which initiates pro-survival signaling. Survivin, a member...

Cite
Lehman CE, Mendez RE, Dougherty MI, et al. Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells. Front Oncol. 2019;9:13doi: 10.3389/fonc.2019.00013.
Lehman, C. E., Mendez, R. E., Dougherty, M. I., Allak, A., Adejumo, O. L., Taniguchi, L. E., Khalil, A., Gioeli, D. G., & Jameson, M. J. (2019). Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells. Frontiers in oncology, 913. https://doi.org/10.3389/fonc.2019.00013
Lehman, Christine E, et al. "Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells." Frontiers in oncology vol. 9 (2019): 13. doi: https://doi.org/10.3389/fonc.2019.00013
Lehman CE, Mendez RE, Dougherty MI, Allak A, Adejumo OL, Taniguchi LE, Khalil A, Gioeli DG, Jameson MJ. Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells. Front Oncol. 2019 Jan 23;9:13. doi: 10.3389/fonc.2019.00013. eCollection 2019. PMID: 30729097; PMCID: PMC6351440.
Copy Download .nbib Format: NLM
Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications.

Journal of neuro-oncology

Steinbach JP, Weller M.
PMID: 15674482
J Neurooncol. 2004 Nov;70(2):247-256. doi: 10.1007/s11060-004-2753-4.

Understanding apoptosis is often considered a key to understand the genesis of tumors and to devise innovative strategies for their treatment. Similar to other types of cancer, essential pathways regulating apoptosis are also disrupted in malignant gliomas, notably the...

Cite
Steinbach JP, Weller M. Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications. J Neurooncol. 2004;70(2):247-256doi: 10.1007/s11060-004-2753-4.
Steinbach, J. P., & Weller, M. (2004). Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications. Journal of neuro-oncology, 70(2), 247-256. https://doi.org/10.1007/s11060-004-2753-4
Steinbach, Joachim P, and Weller, Michael. "Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications." Journal of neuro-oncology vol. 70,2 (2004): 247-256. doi: https://doi.org/10.1007/s11060-004-2753-4
Steinbach JP, Weller M. Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications. J Neurooncol. 2004 Nov;70(2):247-256. doi: 10.1007/s11060-004-2753-4. PMID: 15674482.
Copy Download .nbib Format: NLM
X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy.

Frontiers in oncology

Obexer P, Ausserlechner MJ.
PMID: 25120954
Front Oncol. 2014 Jul 28;4:197. doi: 10.3389/fonc.2014.00197. eCollection 2014.

Defects in apoptosis regulation are one main cause of cancer development and may result from overexpression of anti-apoptotic proteins such as inhibitor of apoptosis proteins (IAPs). IAPs are cell death regulators that, among other functions, bind caspases, and interfere...

Cite
Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol. 2014;4:197doi: 10.3389/fonc.2014.00197.
Obexer, P., & Ausserlechner, M. J. (2014). X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Frontiers in oncology, 4197. https://doi.org/10.3389/fonc.2014.00197
Obexer, Petra, and Ausserlechner, Michael J. "X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy." Frontiers in oncology vol. 4 (2014): 197. doi: https://doi.org/10.3389/fonc.2014.00197
Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol. 2014 Jul 28;4:197. doi: 10.3389/fonc.2014.00197. eCollection 2014. PMID: 25120954; PMCID: PMC4112792.
Copy Download .nbib Format: NLM
Structure-based identification of a new IAP-targeting compound that induces cancer cell death inducing NF-κB pathway.

Computational and structural biotechnology journal

Cossu F, Camelliti S, Lecis D, Sorrentino L, Majorini MT, Milani M, Mastrangelo E.
PMID: 34938412
Comput Struct Biotechnol J. 2021 Nov 26;19:6366-6374. doi: 10.1016/j.csbj.2021.11.034. eCollection 2021.

Inhibitors of apoptosis proteins (IAPs) are validated onco-targets, as their overexpression correlates with cancer onset, progression, diffusion and chemoresistance. IAPs regulate cell death survival pathways, inflammation, and immunity. Targeting IAPs, by impairing their protein-protein interaction surfaces, can affect events...

Cite
Cossu F, Camelliti S, Lecis D, et al. Structure-based identification of a new IAP-targeting compound that induces cancer cell death inducing NF-κB pathway. Comput Struct Biotechnol J. 2021;19:6366-6374doi: 10.1016/j.csbj.2021.11.034.
Cossu, F., Camelliti, S., Lecis, D., Sorrentino, L., Majorini, M. T., Milani, M., & Mastrangelo, E. (2021). Structure-based identification of a new IAP-targeting compound that induces cancer cell death inducing NF-κB pathway. Computational and structural biotechnology journal, 196366-6374. https://doi.org/10.1016/j.csbj.2021.11.034
Cossu, Federica, et al. "Structure-based identification of a new IAP-targeting compound that induces cancer cell death inducing NF-κB pathway." Computational and structural biotechnology journal vol. 19 (2021): 6366-6374. doi: https://doi.org/10.1016/j.csbj.2021.11.034
Cossu F, Camelliti S, Lecis D, Sorrentino L, Majorini MT, Milani M, Mastrangelo E. Structure-based identification of a new IAP-targeting compound that induces cancer cell death inducing NF-κB pathway. Comput Struct Biotechnol J. 2021 Nov 26;19:6366-6374. doi: 10.1016/j.csbj.2021.11.034. eCollection 2021. PMID: 34938412; PMCID: PMC8649670.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 75 entries